TVTX250117P12500
- 0.09
- 0.000.00%
Travere Therapeutic Newsroom
Express News | Travere Therapeutics Inc: Expects Fiscal Year 2024 Net Product Sales to Be Approximately $227 Mln
Express News | Travere Therapeutics Inc: On Track to Provide Regulatory Update on Sparsentan in Fsgs by Its Q4 2024 Earnings Call
Press Release: Travere Therapeutics Provides Corporate Update and 2025 Outlook
Express News | Travere Therapeutics- Snda for Modification of Liver Monitoring for Filspari in Igan Accepted for FDA Review ; Pdufa Target Action Date of Aug 28
Express News | Travere Therapeutics Provides Corporate Update and 2025 Outlook
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability
Cantor Fitzgerald Initiates Travere Therapeutic(TVTX.US) With Buy Rating
Cantor Fitzgerald Initiates Travere Therapeutics at Overweight
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Announces Target Price $24
Travere Therapeutics Insider Sold Shares Worth $258,278, According to a Recent SEC Filing
J.P. Morgan's Top Healthcare Stocks for 2025
Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Raises Target Price to $18
The 3.8% Return This Week Takes Travere Therapeutics' (NASDAQ:TVTX) Shareholders One-year Gains to 124%
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Travere Therapeutics (TVTX) Gets a Buy From J.P. Morgan
Express News | Travere Therapeutics Inc : JP Morgan Cuts Target Price to $42 From $43
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Travere Therapeutics Is Maintained at Neutral by Piper Sandler